A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
=== Osteoid in bone tumors === Osteosarcoma: The most common primary malignant bone tumor, osteosarcoma is characterized by malignant cells that produce osteoid. Osteosarcoma is a primary malignant tumour of the skeleton characterized by the direct formation of immature bone or osteoid tissue by the tumour cells. The production of osteoid by tumor cells is the histological hallmark distinguishing osteosarcoma from other bone tumors. The malignant osteoid produced appears as irregular, immature structures in close proximity to malignant cells with enlarged hyperchromatic nuclei and abnormal mitotic figures. Osteoid osteoma: A benign bone-forming tumor characterized by formation of osteoid tissue, typically causing localized bone pain that worsens at night.
=== General references === Daxer, Albert; Misof, Klaus; Grabner, Barbara; Ettl, Armin; Fratzl, Peter (1998). "Collagen fibrils in the human corneal stroma: Structure and aging". Investigative Ophthalmology & Visual Science. 39 (3): 644–8. PMID 9501878. Daxer, Albert; Fratzl, Peter (1997). "Collagen fibril orientation in the human corneal stroma and its implication in keratoconus". Investigative Ophthalmology & Visual Science. 38 (1): 121–9. PMID 9008637. Fratzl, Peter; Daxer, Albert (1993). "Structural transformation of collagen fibrils in corneal stroma during drying. An x-ray scattering study". Biophysical Journal. 64 (4): 1210–4. Bibcode:1993BpJ....64.1210F. doi:10.1016/S0006-3495(93)81487-5. PMC 1262438. PMID 8494978.
=== Cancer === After inflammation, restoration of normal tissue integrity and function is preserved by feedback interactions between diverse cell types mediated by adhesion molecules and secreted cytokines. Disruption of normal feedback mechanisms in cancer threatens tissue integrity and enables a malignant tumor to escape the immune system. An example of the importance of the wound healing response within tumors is illustrated in work by Howard Chang and colleagues at Stanford University studying breast cancers.
Sources: en.wikipedia.org
==== Data Protection Commission (Europe) ==== In September 2021, the Ireland Data Protection Commission (DPC) launched investigations into TikTok concerning the protection of minors' data and transfers of personal data to China. The Irish DPC became the lead agency to handle such matters after TikTok established an office in the country, taking over investigations started by Dutch and Italian authorities. In September 2023, the DPC fined TikTok €345 million for violations of the General Data Protection Regulation (GDPR) vis-à-vis the mishandling of children data. In April 2025, the Ireland DPC fined TikTok over €500 million for illegally sending European user data to China. In July 2025, the DPC opened a new investigation into TikTok for unauthorized transfers of user data to China.
==== Sucrase ==== Function: Sucrase is a stomachs related protein that mobilizes hydrolysis to convert sucrose into glucose and fructose. Clinical Significance: Low amounts of Sucrose also known as Sucrose intolerance happens when sucrose isn't being discharged in the small digestive tract. A result of this is extra gas.
==== Changes in the Government ==== In the fourth cabinet, of the nineteen appointed ministers, thirteen are re-elected to their positions and six are new ministers, highlighting Heidy Juárez, Silvana Robles, and Cinthya Lindo Espinoza. Following the announcement by Vice President Dina Boluarte that she will not continue as minister, justifying that "the current polarization harms everyone" and preferring to consolidate "the broadest unity of all Peruvians" as vice president, Minister Roberto Sánchez is the longest-serving minister of Pedro Castillo's mandate, since the first cabinet of Guido Bellido. Since November, he has been described by the media as close to the president and is also implicated in the corruption scandals against Pedro Castillo. What is surprising is the appointment of Heidy Juárez as Minister of Women and Vulnerable Populations, she is also a representative and former member of APP, expelled from the group and left for being the author and revealing, according to the APP party, the matter of the audio recordings that caused Lady Camones to be censored from the presidency of Congress by the left and center groups. Following this expulsion, he became a member of the Podemos Perú parliamentary group. However, when she was appointed to the government, she was still a member of the Podemos Perú parliamentary group, but the latter, through the group's president, José Luna Gálvez, expressed its disagreement with this choice, stating that it did not support or was linked to the government.
In another study with escitalopram citalopram, metabolomic analysis of plasma from patients with MDD revealed that variations in glycine metabolism were negatively associated with patient outcome upon treatment with selective serotonin reuptake inhibitors (SSRIs), an important drug class involved in the treatment of this disease.
Sources: en.wikipedia.org
==== Multicenter ESG Randomized Trial (MERIT) ==== The recently published MERIT study is the first and only randomized controlled trial of the ESG for treatment of obesity and included 209 adult subjects with class I and II obesity (BMI 30–40 kg/m2). It was conducted from Dec. 2017 to Jun. 2019, spanned nine centers in the United States, and comprised 85 adults in the ESG arm and 124 adults in the control arm (lifestyle modification only). Subjects in the ESG arm lost 13.6% of body weight and 49.2% of excess body weight at one year, compared to 0.8% total body weight loss and 3.2% excess weight loss in the control arm at the same time point.
=== Agricultural feed === A wide variety of agroindustrial waste products can be fermented to use as food for animals, especially ruminants. Fungi have been employed to break down cellulosic wastes to increase protein content and improve in vitro digestibility.
A review of animal studies by the World Health Organization found no adverse health effects associated with dimethylpolysiloxane. TBHQ is a common preservative for vegetable oils, cereals, nuts, cookies, chips and animal fats, found in other foods such as Girl Scout Cookies and Quaker Chewy Granola Bars. The U.S. Food and Drug Administration sets an upper limit of 0.02% of the oil or fat content in foods, which like other foods, applies to the oil used in McNuggets. Effective use of TBHQ was 1 gram per 5,000 grams of cooking oil (1 gram per 11.023 pounds of cooking oil).
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.